CAJ | 학술논문

目的：探究与分析诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效。方法选取本院自2012年12月~2013年11月收治的初诊重度2型糖尿病患者60例,将其作为临床研究对象,采取随机数字表法分为对照组和观察组,每组各30例,对照组给予诺和锐30治疗,观察组在其基础上加用维格列汀治疗,观察与对比两组患者的临床疗效。结果两组患者治疗后空腹血糖、餐后血糖、HbA1c、甘油三酯、总胆固醇、低密度脂蛋白胆固醇较治疗前显著降低,差异有统计学意义(P<0.05),观察组较对照组降低显著, P<0.05,差异具有统计学意义。结论诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效显著,能够全面降低患者血糖,不良反应少,低血糖发生率低。
목적：탐구여분석낙화예30연합유격렬정치료초진중도2형당뇨병적림상료효。방법선취본원자2012년12월~2013년11월수치적초진중도2형당뇨병환자60례,장기작위림상연구대상,채취수궤수자표법분위대조조화관찰조,매조각30례,대조조급여낙화예30치료,관찰조재기기출상가용유격렬정치료,관찰여대비량조환자적림상료효。결과량조환자치료후공복혈당、찬후혈당、HbA1c、감유삼지、총담고순、저밀도지단백담고순교치료전현저강저,차이유통계학의의(P<0.05),관찰조교대조조강저현저, P<0.05,차이구유통계학의의。결론낙화예30연합유격렬정치료초진중도2형당뇨병적림상료효현저,능구전면강저환자혈당,불량반응소,저혈당발생솔저。
Objective To explore and analyze clinical effect of aspart 30 combined with vildagliptin in the treatment of newly diagnosed severe type 2 diabetes. Methods From December 2012 to November 2013, 60 cases of newly diagnosed severe type 2 diabetic patients were randomly divided into control group and observation group, 30 cases for each group, control group were given aspart treatment, observation group received vildagliptin treatment on its basis, and clinical efficacy of two groups was compared. Results After treatment, levels of fasting plasma glucose, postprandial glucose, HbA1c, TG, TC and LDL-C in observation group decreased significantly compared with control group, P<0.05, statistically significant. Conclusion Aspart 30 combined with vildagliptin therapy can significantly decrease blood sugar of newly severe diagnosed type 2 diabetes with less adverse reaction and low rates of hypoglycemia.